Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Open accessThe DOI matches its Crossref record; 224 of the 227 references it cites were found in a registry or an index.
Abstract
Apolipoprotein E (APOE) genotype is the major genetic risk factor for Alzheimer disease (AD); the 14 allele increases risk and the 12 allele is protective.In the central nervous system (CNS), apoE is produced by glial cells, is present in high-density-like lipoproteins, interacts with several receptors that are members of the low-density lipoprotein receptor (LDLR) family, and is a protein that binds to the amyloid-b (Ab) peptide.There are a variety of mechanisms by which apoE isoform may influence risk for AD.There is substantial evidence that differential effects of apoE isoform on AD risk are influenced by the ability of apoE to affect Ab aggregation and clearance in the brain.Other mechanisms are also likely to play a role in the ability of apoE to influence CNS function as well as AD, including effects on synaptic plasticity, cell signaling, lipid transport and metabolism, and neuroinflammation.ApoE receptors, including LDLRs, Apoer2, very low-density lipoprotein receptors (VLDLRs), and lipoprotein receptor-related protein 1 (LRP1) appear to influence both the CNS effects of apoE as well as Ab metabolism and toxicity.Therapeutic strategies based on apoE and apoE receptors may include influencing apoE/Ab interactions, apoE structure, apoE lipidation, LDLR receptor family member function, and signaling.Understanding the normal and disease-related biology connecting apoE, apoE receptors, and AD is likely to provide novel insights into AD pathogenesis and treatment.A lzheimer disease (AD), specifically the late- onset form of AD (LOAD), is the most common cause of dementia in individuals older than 60 years of age.Although mutations in the genes PS1, PS2, and APP cause less common forms of early-onset, autosomal dominant familial AD (FAD), these cases represent ,1% of AD.In addition to the genes that cause FAD, LOAD also has a strong genetic component.Although several susceptibility genes for AD have been reported, by far the strongest genetic risk factor for LOAD is apolipoprotein
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those who inherit one copy of the e4 form have about three times the risk of developing Alzheimer's compared with those with two copies of the e3 form, while those who inherit two copies of the e4 form have an estimated eight-to 12-fold risk.[73][74][75]”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, LDLR and LRP1 disruption by PCSK9 may be crucial for AD progression since they are the major ApoE receptors in the brain, are involved in lipid homeostasis and intracellular signaling, and are fundamental for the regulation of neuronal structure and synaptogenesis [79].”
From The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoE isoforms may differentially regulate brain lipid metabolism in AD and primary tauopathies.1”
From Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist (2024) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single copy of the ε4 allele increases disease risk by approximately four-fold while two copies of the allele increase disease risk by approximately twelvefold relative to individuals who are ε3/ε3 [1, 4, 5].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the brain most cholesterol is produced de novo by astrocytes, and then transported to neurons and other cells by combining with ApoE, mainly synthesized by astrocytes, to form lipoproteins that are secreted through the ATP-binding cassette (ABC) transporters [9,10].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [9]
Experimental — accuracy not yet measured
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“…and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008;…”
BackgroundRetractedCorder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 3×
“…Cite this article as Cold Spring Harb Perspect Med 2012;2:a006312 1 w w w .p er sp ec ti ve si n m ed ic in e. o rg E (APOE) genotype, with the 14 allele being an AD risk factor and the 12 allele being protective relative to the prevalent 13 allele (Corder et al. 1993; Strittmatter et al. 1993a).”
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“…to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008; Nygaard and Strittmatter 2009; Gimbel et al.…”
BackgroundWalsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · cited 1×
“…oligomers are strong inducers of synaptic suppression, and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman…”
BackgroundStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 4×
“…Cite this article as Cold Spring Harb Perspect Med 2012;2:a006312 1 w w w .p er sp ec ti ve si n m ed ic in e. o rg E (APOE) genotype, with the 14 allele being an AD risk factor and the 12 allele being protective relative to the prevalent 13 allele (Corder et al. 1993; Strittmatter et al. 1993a).”
BackgroundInfluentialApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · cited 17×
“In contrast, apoAI in CNS is derived from the periphery (SorciThomas et al. 1988).”
BackgroundInfluentialShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685 · cited 1×
“…Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008; Nygaard and Strittmatter 2009; Gimbel et al. 2010; Palop and Mucke 2010; Renner et al. 2010; Ronicke et al. 2010) (see Mucke and…”
BackgroundDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 2×
“Ab1-42 oligomers are strong inducers of synaptic suppression, and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo e…”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“Interestingly, single-nucleotide polymorphisms in clusterin have been shown to be a risk factor for AD (Harold et al. 2009; Lambert et al. 2009).”
BackgroundThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“1) (Zlokovic 2008).”
Research works printed but not linked: 1
- Sanan DA, Weisgraber KH, Russel SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewksi T, Frangione B, Roses B, et al. 1994. Apolipoprotein E associates with b amyloid peptide of Alzheimer's disease to form novel monofibrils. J Clin Invest 94: 860 -869.
Cited by
Items 401–500 of 810
Gallego, I., Villate-Beitia, I., del Burgo, L. S., Puras, G., & Pedraz, J. L. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000418 · Cited by 33
“In particular, the APOE4 e4 allele is present in around 14% of the general population and in 40–60% of all cases of AD as one -showing 3.5-fold higher risk of developing AD, or two copies, increasing the risk by 8–15-fold (Holtzman et al., 2012; Michaelson, 2014).”
BackgroundInfluentialMhatre‐Winters, I., Eid, A., Han, Y., Tieu, K., & Richardson, J. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179829 · Cited by 26
Circulating Cholesterol Levels May Link to the Factors Influencing Parkinson’s Risk
Zhang, L., Wang, X., Wang, M., Sterling, N. W., Du, G., Lewis, M. M., Yao, T., Mailman, R. B., Li, R., & Huang, X. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00501 · Cited by 29
Qin, Q., & Li, Y. (2019) · Journal of Medical Virology · doi:10.1002/jmv.25481 · Cited by 27
“perform multiple functions within the brain related to lipid transport, regulation of lipid metabolism, synaptic plasticity, cell signaling, and neuroinflammation.(68) The ε4 allele of APOE is the strongest genetic risk factor among its 3 polymorphic alleles (ε2, ε3, and ε4).”
BackgroundSoluble Epoxide Hydrolase and Brain Cholesterol Metabolism
Domingues, M. F., Callai-Silva, N., Piovesan, A. R., & Carlini, C. R. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00325 · Cited by 28
“Soluble epoxide hydrolase also plays a pivotal role in the regulation of endothelial nitric oxide (NO) synthase (eNOS) activity and NO-mediated endothelial cell functions (Hou et al., 2011).”
BackgroundInfluentialFerguson, A. C., Tank, R., Lyall, L. M., Ward, J., Celis-Morales, C., Strawbridge, R., Ho, F., Whelan, C. D., Gill, J., Welsh, P., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200338 · Cited by 25
“The exact mechanisms by which APOE genotype influ-ences brain aging are unclear but probably due to pleiotropic pathways stemming from its core role in lipid metabolism [4].”
CSF ApoE predicts clinical progression in nondemented APOEε4 carriers
van Harten, A. C., Jongbloed, W., Teunissen, C. E., Scheltens, P., Veerhuis, R., & van der Flier, W. M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.04.002 · Cited by 26
Medoro, A., Bartollino, S., Mignogna, D., Passarella, D., Porcile, C., Pagano, A., Florio, T., Nizzari, M., Guerra, G., Marco, R. D., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170628 · Cited by 26
“PP common cytosolic signaling adaptors such as FE65, X11/Mint, and Disabled-1 (Dab1), and all are receptors for apolipoprotein E (ApoE) [67].”
Axl receptor tyrosine kinase is a regulator of apolipoprotein E
Zhao, W., Fan, J., Kulic, I., Koh, C., Clark, A., Meuller, J., Engkvist, O., Barichievy, S., Raynoschek, C., Hicks, R., et al. (2020) · Molecular Brain · doi:10.1186/s13041-020-00609-1 · Cited by 25
Staurenghi, E., Leoni, V., Lo Iacono, M., Sottero, B., Testa, G., Giannelli, S., Leonarduzzi, G., & Gamba, P. (2022) · Antioxidants · doi:10.3390/antiox11112168 · Cited by 24
“ApoE is able to bind various receptors such as LDLR, LRP1, and ApoER2, through which ApoE-containing lipoproteins are taken up by cells [9].”
BackgroundOkoro, E. U. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126236 · Cited by 18
“Since apoE plays a major role in binding several lipoprotein receptors of the LDLR family [67,68], the effect of apoE depletion on TNFɑinduced Dil-LDL intracellular levels was investigated.”
BackgroundTranscriptional and Post-Transcriptional Regulations of Amyloid-β Precursor Protein (APP) mRNA
Sato, K., Takayama, K., Hashimoto, M., & Inoue, S. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.721579 · Cited by 26
The cholesteryl ester transfer protein (CETP) raises cholesterol levels in the brain
Oestereich, F., Yousefpour, N., Yang, E., Phénix, J., Nezhad, Z. S., Nitu, A., Cobá, A. V., Ribeiro‐da‐Silva, A., Chaurand, P., & Munter, L. M. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100260 · Cited by 26
“APOE, apolipoprotein E; CETP, cholesteryl ester transfer protein; CETPtg, CETP transgenic; GFAP, glial fibrillary acidic protein; GLAST, glutamate aspartate transporter; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; IMS, imaging mass spectrometry; LDLR, LDL receptor; LRP1, LDLR-related protein 1; qPCR, quant…”
BackgroundMethodInfluentialMuñoz, S. S., Li, H., Ruberu, K. R., Chu, Q., Saghatelian, A., Ooi, L., & Garner, B. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001278 · Cited by 26
“Based on the knowledge that apoE provides neurotrophic support via its interactions with LDL receptor family members (1, 7, 34, 61, 62), and that the apoE 25 kDa fragment we have identified is stable in vitro and in vivo, it is plausible that this fragment may also promote neuritogenic effects via interaction with LDL…”
BackgroundResultNeuroprotective Effects of the FGF21 Analogue LY2405319
Rühlmann, C., Dannehl, D., Brodtrück, M., Adams, A. C., Stenzel, J., Lindner, T., Krause, B. J., Vollmar, B., & Kuhla, A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200837 · Cited by 27
“:3) aggregation [8, 30, 31].”
van der Spek, S. J. F., Gonzalez‐Lozano, M. A., Koopmans, F., Miedema, S. S. M., Paliukhovich, I., Smit, A. B., & Li, K. W. (2021) · Cells · doi:10.3390/cells10071588 · Cited by 27
“This activated group of microglia was characterized by increased expression of Apoe [33–35], an apolipoprotein involved in lipoprotein homeostasis and clearance of Aβ [37,38].”
BackgroundAsih, P. R., Chatterjee, P., Verdile, G., Gupta, V. B., Trengove, R. D., & Martins, R. N. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.29 · Cited by 25
Genetic Determinants of “Cognitive Impairment, No Dementia”
Dubé, J. B., Johansen, C. T., Robinson, J. F., Lindsay, J., Hachinski, V., & Hegele, R. A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121477 · Cited by 24
“plaque deposition and neurofibrillary tangles [10, 11].”
Gain and loss events in the evolution of the apolipoprotein family in vertebrata
Liu, J.-Q., Li, W., Zheng, J., Tian, Q.-N., Huang, J., & Dai, S. (2019) · BMC Evolutionary Biology · doi:10.1186/s12862-019-1519-8 · Cited by 24
Aichholzer, F., Klafki, H., Ogorek, I., Vogelgsang, J. S., Wiltfang, J., Scherbaum, N., Weggen, S., & Wirths, O. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00828-1 · Cited by 25
“ApoE is an important protein involved in cholesterol transport, and ApoE isoforms differentially affect brain clearance of Aβ peptides [53].”
BackgroundA putative role for lncRNAs in epigenetic regulation of memory
Irwin, A. B., Bahabry, R., & Lubin, F. D. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105184 · Cited by 25
Asante, I., Louie, S. G., & Yassine, H. N. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14907 · Cited by 26
Retracted: Advances in the physiological and pathological implications of cholesterol
Cortés, V., Busso, D., Mardones, P., Alberto Maiz, G., Arteaga, A., Nervi, F. O., & Rigotti, A. (2013) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12025 · Cited by 29
“However, given the multiplicity of functions of APOE and its receptors in the CNS, it has been extremely difficult to pinpoint the exact mechanism(s) underlying this association (Hauser, Narayanaswami & Ryan, 2011; Schipper, 2011; Holtzman et al., 2012).”
RetractedTwo Alzheimer’s disease risk genes increase entorhinal cortex volume in young adults
DiBattista, A. M., Stevens, B. W., Rebeck, G. W., & Green, A. E. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00779 · Cited by 24
“…family of cell surface receptors (Kounnas et al., 1995; Leeb et al., 2014) that promote neurite outgrowth (Nathan et al., 1994; Kang et al., 2005), cholesterol metabolism (for review, see Holtzman et al., 2012), and clearance of the AD pathological hallmark, amyloid-β (Demattos et al., 2004).”
BackgroundInfluentialDuff, K. M., Suhrie, K. R., Hammers, D. B., Dixon, A. M., King, J. B., Koppelmans, V., & Hoffman, J. M. (2021) · The Clinical Neuropsychologist · doi:10.1080/13854046.2021.1995050 · Cited by 23
“To our knowledge, no studies have examined the relationship between the RBANS and APOE ε4 allele carrier status in older adults, which is another biomarker of AD (Holtzman et al., 2012; Mayeux et al., 1993; Petersen et al., 1995).”
BackgroundOikawa, N., Hatsuta, H., Murayama, S., Suzuki, A., & Yanagisawa, K. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23341 · Cited by 23
“…confirmed that the APOE alleles can affect the risk of AD through a wide range of biological functions of apolipoprotein E, not through a simple function, such as the regulation of lipid transport, glucose metabolism, or neuroinflammation (for review see Holtzman et al., 2012; Liu et al., 2013).”
BackgroundHirtz, C., Vialaret, J., Nouadje, G., Schraen‐Maschke, S., Benlian, P., Mary, S., Philibert, P., Tiers, L., Bros, P., Delaby, C., et al. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.12.020 · Cited by 23
“the amino acid substitutions, three isoforms ApoE2 (cys112, cys158), ApoE3 (cys112, arg158), and ApoE4 (arg112, arg158) are thus generated [1].”
APOE polymorphism in ATTR amyloidosis patients treated with lipid nanoparticle siRNA
Niemietz, C., Nadzemova, O., Zibert, A., & Schmidt, H. H.-J. (2020) · Amyloid · doi:10.1080/13506129.2019.1681392 · Cited by 22
Bratosiewicz‐Wąsik, J., Liberski, P. P., Pepłońska, B., Styczyńska, M., Smoleń‐Dzirba, J., Cycoń, M., & Wąsik, T. J. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.010 · Cited by 22
Hua, J., Paco, E. G. D., Linck, N., Maurice, T., Desrumaux, C. M., Manoury, B., Rassendren, F., & Ulmann, L. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04784-x · Cited by 23
“Three ApoE alleles exist in the human population, ε2, ε3 and ε4, with ε4 being the strongest genetic risk factor of sporadic AD identified so far [9].”
BackgroundBehan, J. A., Xie, Z., Wang, Y., Yang, X., Aastrup, T., Yan, Y., Adumeau, L., & Dawson, K. A. (2023) · JACS Au · doi:10.1021/jacsau.3c00084 · Cited by 22
Greda, A. K., Gomes, J. P., Schmidt-Krueger, V., Zurawska-Plaksej, E., Fritsche-Guenther, R., Rudolph, I.-M., Telugu, N. S., Cömert, C., Kirwan, J., Kunz, S., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01389-5 · Cited by 21
“This observation is important as APOE ε4 represents the major genetic risk factor for sporadic Alzheimer disease, increasing disease risk in homozygous carriers by 12-fold as compared to carriers of the common APOE ε3/ε3 genotype 16 .”
The Low-Density Lipoprotein Receptor-Related Protein-1 Is Essential for Dengue Virus Infection
Huerta, V., Martin, A. M., Sarría, M., Guirola, O., Yero, A., Ramos, Y., Gómez, D. P., Martín, D., Carletti, T., González‐Lodeiro, L. G., et al. (2024) · Viruses · doi:10.3390/v16111692 · Cited by 22
Woltjer, R. L., Reese, L. C., Richardson, B. E., Tran, H. T. D., Green, S., Pham, T., Chalupsky, M., Gabriel, I., Light, T. J., Sanford, L., et al. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.10.012 · Cited by 23
“ApoE is the major lipoprotein of the brain, where its endogenous function is to traffic lipids and lipophilic substances (Holtzman et al., 2012; Liu et al., 2013).”
BackgroundDu, S., Wang, H., Cai, J., Ren, R., Zhang, W., Wei, W., & Shen, X. (2020) · Biochemistry and Cell Biology · doi:10.1139/bcb-2018-0230 · Cited by 22
Zetterberg, H., Lautner, R., Skillbäck, T. B., Rosén, C., Shahim, P., Mattsson, N., & Blennow, K. (2014) · Advances in clinical chemistry · doi:10.1016/b978-0-12-800141-7.00005-x · Cited by 25
Do Microglia default on network maintenance in Alzheimer's disease?
Southam, K. A., Vincent, A. J., & Small, D. H. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151075 · Cited by 20
“and reduced receptor-mediated A clearance [16].”
Apolipoprotein E Facilitates Amyloid-β Oligomer-Induced Tau Phosphorylation
Hou, T.-T., Han, Y.-D., Cong, L., Liu, C.-C., Liang, X.-Y., Xue, F.-Z., & Du, Y.-F. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190711 · Cited by 20
“Moreover, ApoE can also combine with A (cid:2) and transport A (cid:2) to glial cells or across the blood-brain barrier for further clearance [20].”
Xiang, J. Y., Zhu, W., Yang, F., Yu, Z., Cai, M., Li, X., Zhang, J.-S., Zhang, W., & Cai, D.-F. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00864-9 · Cited by 20
Advances in Genetic and Molecular Understanding of Alzheimer’s Disease
Ibáñez, L., Cruchaga, C., & Fernández, M. V. (2021) · Genes · doi:10.3390/genes12081247 · Cited by 22
A meta-analysis of the relationship between sleep and β-Amyloid biomarkers in Alzheimer’s disease
Harenbrock, J., Holling, H., Reid, G., & Koychev, I. G. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100068 · Cited by 24
Study of Exosomes Shed New Light on Physiology of Amyloidogenesis
van Niel, G. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0357-0 · Cited by 20
Zhang, T., Wang, S., & Niu, Q. L. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-9995-6 · Cited by 20
Zhu, Y., Initiative, O. B. O. A. D. N., Gong, L., He, C., Wang, Q., Ren, Q., & Xie, C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190254 · Cited by 21
Wu, S., Hsu, L., Teng, M., Lin, J.-F., Chou, H., Lee, M., Yi-ming, W., Su, C.-W., & Ko, Y. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0262-z · Cited by 21
“circulating concentrations of lipoproteins and plasma levels of cholesterol and triglycerides [2, 3].”
BackgroundTranscriptional regulation of APP by apoE: To boldly go where no isoform has gone before
Lee, L. C., Goh, M. Q. L., & Koo, E. H. (2017) · BioEssays · doi:10.1002/bies.201700062 · Cited by 22
“Subsequent studies convincingly confirmed the predicted apoE isoform-specific effects in brain such that amyloid burden is highest in mice expressing human apoE4 isoform, followed by apoE3 and lowest in apoE2 [17].”
BackgroundInfluentialApolipoprotein E‐ε4 deficiency and cognitive function in hepatitis C virus‐infected patients
Wozniak, M. A., Iparraguirre, L. M. L., Dirks, M., Deb‐Chatterji, M., Pflugrad, H., Goldbecker, A., Tryc, A. B., Worthmann, H., Gess, M., Crossey, M. M. E., et al. (2015) · Journal of Viral Hepatitis · doi:10.1111/jvh.12443 · Cited by 20
Omari, Z., Sasaki, K., Sabti, M., Bejaoui, M., Hafidi, A., Gadhi, C., & Isoda, H. (2021) · Aging · doi:10.18632/aging.202516 · Cited by 22
“On the other hand, our results show no significant changes in the concentration of dopamine and adrenaline compared to aged water-treated mice, which contradicts the literature that reports that the levels of dopamine [44–46] and adrenaline in the rat and mice brain decrease with aging [47, 48].”
Resultden Hoedt, S., Crivelli, S. M., Leijten, F. P. J., Losen, M. H., Stevens, J., Mané-Damas, M., de Vries, H. E., Walter, J., Mirzaian, M., Sijbrands, E. J. G., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.765252 · Cited by 20
Amyloid‐β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects
Yu, Y., Yu, S., Battaglia, G., & Tian, X. (2024) · Ibrain · doi:10.1002/ibra.12155 · Cited by 38
“79 APOE encompasses three main subtypes, APOE4, APOE3, and APOE2, among which APOE 4 has a damaging effect, and APOE3 and APOE2 have a protective effect.”
BackgroundPotential Therapeutic Implications of Gelsolin in Alzheimer's Disease
Ji, L., Zhao, X., & Hua, Z. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-141548 · Cited by 24
“Strong evidence suggests that differential effects of ApoE isoform on AD risk are influenced by their ability to affect A aggregation and clearance in the brain [10].”
Zheng, J., Yan, H., Shi, L., Kong, Y., Zhao, Y., Xie, L., Li, J., Huang, M., Li, J., & Zhao, S. (2016) · Medicine · doi:10.1097/md.0000000000004742 · Cited by 19
“Individuals homozygous for APOE e4 have an approximately 12-fold increased risk for AD, compared with patients lacking APOE e4, and an average age at onset of approximately 65 years, while heterozygous carriers have about a 3-fold increased risk and an average age at onset of approximately 75 years.([24]) It is clear…”
BackgroundZhu, L., Shu, H., Liu, D., Guo, Q., Wang, Z., & Zhang, Z. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00289 · Cited by 19
“Neuropathological studies in human and animal models have proved that APOE ε4 has a physical interaction with Aβ, which has a strong influence on memory deficit in probable preclinical AD (Holtzman et al., 2012).”
BackgroundAnalysis of Human Blood Plasma Proteome from Ten Healthy Volunteers from Indian Population
Gautam, P., Nair, S. C., Ramamoorthy, K., Swamy, C. V. B., & Nagaraj, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072584 · Cited by 20
“Apolipoprotein E (APOE) is largely produced by glial cells and its genotype is reported to be one of the major genetic risk factor for Alzheimer disease [22].”
The Nexus of Aβ, Aging, and Sleep
Gerstner, J. R., Perron, I. J., & Pack, A. I. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004815 · Cited by 23
“Binding of apoE to Aβ is thought to be one mechanism for clearing Aβ and preventing its aggregation in the brain (1).”
BackgroundInfluentialEngelman, C. D., Darst, B. F., Bilgel, M., Vasiljevic, E., Koscik, R. L., Jedynak, B., & Johnson, S. C. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.025 · Cited by 19
“Carrying one copy of the APOE 4 allele results in a three-fold higher risk of developing AD than those with two copies of the more common 3 allele, and those with two copies of the 4 allele have an 8-to 12-fold higher risk (Holtzman, et al., 2012,Loy, et al., 2014).”
Dolci, G., Cruciani, F., Rahaman, M. A., Abrol, A., Chen, J., Fu, Z., Galazzo, I. B., Menegaz, G., Calhoun, V. D., & Initiative, A. D. N. (2025) · Journal of Neural Engineering · doi:10.1088/1741-2552/ae087d · Cited by 24
“More in-depth, the ApolipoproteinE is a ligand receptor-mediated endocytosis of lipoprotein particles [96] and is the major cholesterol transport and other lipids in the brain [97, 98].”
Zhao, X., Li, Y., Zhang, S., Sudwarts, A., Zhang, H., Kozlova, A., Moulton, M. J., Goodman, L. D., Pang, Z. P., Sanders, A. R., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00840-1 · Cited by 19
“Accumulation of Aβ and tau lesions have been central to the postulated pathogenic mechanism underlying the APOE risk locus [8, 9].”
Kong, C., Xie, H., Gao, Z., Shao, M., Li, H., Shi, R., Cai, L., Gao, S., Sun, T., & Li, C. (2019) · Virologica Sinica · doi:10.1007/s12250-019-00124-1 · Cited by 18
“It is estimated that people with one e4 allele are three times more likely to develop AD than those with two e3 alleles, whereas people with two e4 alleles have a 8–12 times higher risk of developing AD (Holtzman et al. 2012; Loy et al. 2014).”
BackgroundLiu, B., Chen, B., Yi, J., Long, H., Wen, H., Tian, F., Liu, Y., Xiao, L., & Li, L. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.949298 · Cited by 24
Are the Effects ofAPOEɛ4 on Cognitive Function in Nonclinical Populations Age- and Gender-Dependent?
Rusted, J. M., & Carare, R. O. (2015) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.43 · Cited by 22
Association of Apolipoprotein E Polymorphism with Impact on Overweight University Pupils
Alharbi, K. K., Syed, R., Alharbi, F. K., & Khan, I. A. (2017) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2016.0190 · Cited by 20
“APOE is a major lipoprotein within the central nervous system and is hypothesized to stimulate neurite outgrowth in response to cellular injury and degeneration (Holtzman et al. , 2012).”
Venzi, M., Tóth, M., Häggkvist, J., Bogstedt, A., Rachalski, A., Mattsson, A., Frumento, P., & Farde, L. (2017) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-170006 · Cited by 18
Xiao, H., Gao, Y., Liu, L., & Li, Y. (2017) · EXCLI journal · doi:10.17179/excli2017-289 · Cited by 16
“Epidemiologic studies have identified that these isoforms are the main genetic determinants of the progression of AD (Holtzman et al., 2012).”
BackgroundRao, W., Zhang, Y., Li, K., & Zhang, X. (2021) · Aging · doi:10.18632/aging.203161 · Cited by 17
“The Apolipoprotein E (ApoE) gene (4 exons and 3 introns) plays a key role in receptor-mediated endocytosis of lipoproteins in the brain [72] and affects downstream proteins, such as brain-derived neurotrophic factor (BDNF) [73, 74], which may be involved in neuropsychiatric genetics [74, 75], especially in cognition-r…”
BackgroundUpdate on Major Neurocognitive Disorders
Jones, K. C. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20210004 · Cited by 21
Goikolea, J., Gereñu, G., Daniilidou, M., Mangialasche, F., Mecocci, P., Ngandu, T., Rinne, J. O., Solomon, A., Kivipelto, M., Cedazo-Mínguez, Á., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00979-9 · Cited by 19
Gan, K. J., Morihara, T., & Silverman, M. A. (2014) · BioEssays · doi:10.1002/bies.201400131 · Cited by 17
Cope, Z. A., Murai, T., & Rizzo, S. J. S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.805063 · Cited by 18
Sánchez-Melgar, A., Izquierdo-Ramírez, P. J., Griñán‐Ferré, C., Pallàs, M., Martín, M., & Albasanz, J. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147580 · Cited by 17
“Thus, since ApoE primarily binds to LDL-R and LDLR-related protein 1 (LRP1) in the brain, mediating the endocytosis and clearance of ApoE lipoproteins [66], the overexpression of LDL-R is an effective approach to significantly induce ApoE reduction and consequent alleviation of pathologic changes in AD mouse models [6…”
BackgroundThe Mevalonate Pathway in Alzheimer’s Disease — Cholesterol and Non-Sterol Isoprenoids
Mohamed, A., Smith, K. T., & Chaves, E. (2015) · InTech eBooks · doi:10.5772/59904 · Cited by 24
“Neurons import cholesterol via lipoprotein receptor-mediated endocytosis [31].”
BackgroundRashidi, O. M., H.Nazar, F. A., Alama, M. N., & Awan, Z. A. (2017) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401711010084 · Cited by 18
“The interaction activity of the APOE-LDLR complex has been pointed as an essential cellular activity for mediation of cholesterol metabolism, as the functional interaction between both proteins had already been associated with the risk of CVD [39].”
BackgroundМалашенкова, И. К., Krynskiy, S., Mamoshina, M. V., & Didkovsky, N. A. (2018) · Medical Immunology (Russia) · doi:10.15789/1563-0625-2018-3-303-312 · Cited by 17
Lagger, C., Ursu, E., Equey, A., Avelar, R. A., Pisco, A. O., Tăcutu, R., & de Magalhães, J. P. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.13.456238 · Cited by 19
“App is the precursor of amyloid beta (Aβ) peptides 64 , Apoe is a known regulator of Aβ clearance 65 and interactions between App and Apoe receptors influence Aβ metabolism and toxicity 66,67 .”
BackgroundEndo-lysosomal dysfunction and neuronal–glial crosstalk in Niemann–Pick type C disease
Malara, M., Prestel, M., & Tahirović, S. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2022.0388 · Cited by 20
Kulkarni, P. G., Mohire, V. M., Waghmare, P. P., & Banerjee, T. (2024) · Mitochondrion · doi:10.1016/j.mito.2024.101874 · Cited by 16
Failure analysis of clinical trials to test the amyloid hypothesis
Hyman, B. T., & Sorger, P. K. (2014) · Annals of Neurology · doi:10.1002/ana.24227 · Cited by 16
Soyal, S. M., Kwik, M., Kalev, O., Lenz, S., Zara, G., Strasser, P., Patsch, W., & Weis, S. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1317 · Cited by 17
“This is in stark contrast with the TOMM40/APOE-E4 encoding haplotypes that were associated with both intermediate and high likelihood AD and may reflect the deficient clearance of Aβ by the E4 protein (Holtzman et al., 2012).”
ResultBrain-targeted nanoparticles to overcome the blood-brain barrier
Seko, I., ŞAHİN, A., Tonbul, H., & Çapan, Y. (2020) · Journal of Pharmaceutical Technolgy · doi:10.37662/jpt.2020.4 · Cited by 18
“When compared to APOE4 non-carriers, APOE4 carriers can be exposed to BBB disruption, neurovascular unit dysfunction including pericyte degeneration, decreased glucose uptake and damaged cerebrovascular activity [36-41].”
BackgroundInfluentialPark, S., Setiawan, V. W., White, L. R., Wu, A. H., Cheng, I., Haiman, C. A., Wilkens, L. R., Le Marchand, L., & Lim, U. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12677 · Cited by 16
Polazzi, E., Mengoni, I., Peña-Altamira, E., Massenzio, F., Virgili, M., Petralla, S., & Monti, B. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000222 · Cited by 15
“We tested whether constitutive release of ApoE by microglia was altered under different conditions of activation, a common occurrence in various types of CNS pathology 2015 American Association of Neuropathologists, Inc. 821 Copyright © 2015 by the American Association of Neuropathologists, Inc. Unauthorized reproduct…”
BackgroundInfluentialApoER2: Functional Tuning Through Splicing
Gallo, C. M., Ho, A., & Beffert, U. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00144 · Cited by 16
“Alternative splicing generates unique transcripts from the same gene, creating isoforms with altered stability, localization, translation competency or coding sequence (Hughes, 2006; Li et al., 2007).”
BackgroundEkuni, D., Endo, Y., Tomofuji, T., Azuma, T., Irie, K., Kasuyama, K., & Morita, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074966 · Cited by 17
“Further studies are required to investigate the complex relationship between apoE deficiency and Aβ production, because whether increasing or decreasing human apoE levels is required to reduce Aβ levels remains unanswered [1].”
BackgroundTherapeutic Idol reduction ameliorates amyloidosis and improves cognitive function in APP/PS1 mice
Gao, J., Littman, R., Diamante, G., Xiao, X., Ahn, I. S., Yang, X., Cole, T. A., & Tontonoz, P. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00518-19 · Cited by 15
“metabolism, acting to mediate the uptake and degradation of ApoE-containing lipoprotein particles by brain cells (7).”
BackgroundPankiewicz, J. E., Lizińczyk, A. M., Franco, L. A., Diaz, J. R., Martá-Ariza, M., & Sadowski, M. J. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01261-z · Cited by 15
“Apolipoprotein (apo) E is a 34 kDa protein, which is primarily expressed by astrocytes and secreted as highdensity lipoprotein (HDL) like particles [18, 25, 40].”
BackgroundLipid nanoparticles: A delicate nucleic acid delivery system to be further explored
Ma, R., Li, Y., Su, Y., Chen, P., Xie, S., Tan, W., & Liu, X. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102586 · Cited by 15
de Jager, M., Drukarch, B., Hofstee, M. I., Brevé, J. J. P., Jongenelen, C. A. M., Bol, J. G. J. M., & Wilhelmus, M. M. M. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13203 · Cited by 17
Kerr, D. S., Stella, F., Radanovic, M., Aprahamian, I., Bertolucci, P. H. F., & Forlenza, O. V. (2016) · Bipolar Disorders · doi:10.1111/bdi.12367 · Cited by 16
Cathepsin D: A Candidate Link between Amyloid ?-protein and Tauopathy in Alzheimer Disease
Suire, C. N., & Leissring, M. A. (2021) · Journal of Experimental Neurology · doi:10.33696/neurol.2.029 · Cited by 34
“Of note, this trafficking is mediated by apolipoprotein E (ApoE), the strongest genetic risk factor for late-onset AD [18,19].”
BackgroundThe Interplay of Apoes with Syndecans in Influencing Key Cellular Events of Amyloid Pathology
Hudák, A., Jósvay, K., Domonkos, I., Letoha, A., Szilák, L., & Letoha, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137070 · Cited by 16
“ApoE is expressed by several cell types, with the highest expression in the liver and the CNS [2,4,5].”
BackgroundThe apolipoprotein receptor LRP3 compromises APP levels
Cuchillo‐Ibáñez, I., Lennol, M. P., Escamilla, S., Mata‐Balaguer, T., Valverde-Vozmediano, L., López‐Font, I., Ferrer, I., & Sáez‐Valero, J. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00921-5 · Cited by 16
Apolipoprotein E Isoform-specific changes related to stress and trauma exposure
Torres, E. R. S., Luo, J., Boehnlein, J. K., Towns, D., Kinzie, J. D., DeBarber, A. E., & Raber, J. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01848-7 · Cited by 15
“These E2 effects might involve the low-density lipoprotein receptor (LDLR), the major apoE receptor in the CNS [23].”
BackgroundApolipoprotein ε in Brain and Retinal Neurodegenerative Diseases
Abyadeh, M., Gupta, V., Paulo, J. A., Sheriff, S., Shadfar, S., Fitzhenry, M. J., Amirkhani, A., Gupta, V. B., Salekdeh, G. H., Haynes, P. A., et al. (2023) · Aging and Disease · doi:10.14336/ad.2023.0312-1 · Cited by 28
“BBB-associated pericytes have been implicated to mediate uptake of Aβ through a LRP1/ApoE isoformspecific mechanism, which is lower in E4 carriers compared to E3 carriers [100].”
Chaves, G. S., Özel, R. E., Rao, N. V., Hadiprodjo, H., Costa, Y. D., Tokuno, Z., & Pourmand, N. (2017) · Heliyon · doi:10.1016/j.heliyon.2017.e00381 · Cited by 15
“E (APOE) receptor and the interaction of these two proteins has important implications in lipid metabolism [66].”
BackgroundTrkB Signaling Influences Gene Expression in Cortistatin-Expressing Interneurons
Maynard, K. R., Kardian, A., Hill, J. L., Mai, Y., Barry, B. K., Hallock, H. L., Jaffe, A. E., & Martinowich, K. (2020) · eNeuro · doi:10.1523/eneuro.0310-19.2019 · Cited by 15
“We also observed expected depletion of genes such as Mal, which is implicated in myelination (Schaeren-Wiemers et al., 1995a), and Apoe, which is synthesized in astrocytes (Holtzman et al., 2012).”
BackgroundAPOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid1
Berger, M., Cooter, M., Roesler, A. S., Chung, S., Park, J., Modliszeski, J. L., VanDusen, K. W., Thompson, J. W., Moseley, M. A., Devinney, M. J., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200747 · Cited by 15
“Individuals carrying a single APOE4 allele copy have a ~3-fold increased risk of developing Alzheimer’s disease (AD), and those who carry two APOE4 alleles have a greater than 10-fold risk of developing AD [2-5].”
Testa, G., Giannelli, S., Staurenghi, E., Cecci, R., Floro, L., Gamba, P., Sottero, B., & Leonarduzzi, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413637 · Cited by 16
“It However, LDLR and LRP1 disruption by PCSK9 may be crucial for AD progression since they are the major ApoE receptors in the brain, are involved in lipid homeostasis and intracellular signaling, and are fundamental for the regulation of neuronal structure and synaptogenesis [79].”
ApoE-calypse tau: ApoE–tau synergy in Alzheimer’s disease
Lennol, M. P., Bordier, C., Kamelher, L., Ulrich, J. D., Holtzman, D. M., & Gratuze, M. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20250965 · Cited by 15
Self-citationGao, H., Zheng, W., Li, C., & Xu, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111582 · Cited by 16
Nuclear SphK2/S1P signaling is a key regulator of ApoE production and Aβ uptake in astrocytes
Komai, M., Noda, Y., Ikeda, A., Kaneshiro, N., Kamikubo, Y., Sakurai, T., Uehara, T., & Takasugi, N. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100510 · Cited by 13
Metadata
- Authors
- Holtzman, D. M., Herz, J., & Bu, G.
- Affiliations
- Washington University in St. Louis (US)
- The University of Texas at Dallas (US)
- Mayo Clinic in Florida (US)
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-01-10
- Volume
- 2
- Issue
- 3
- Pages
- a006312-a006312
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3282491
- OpenAlex
- W2143955562
- Cited by
- 782
- References
- 227
- Citations by year
- 2026: 39 · 2025: 45 · 2024: 39 · 2023: 51 · 2022: 76 · 2021: 79 · 2020: 67 · 2019: 66 · 2018: 51 · 2017: 51 · 2016: 60 · 2015: 42 · 2014: 59 · 2013: 41 · 2012: 14
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute on Aging (P01AG030128, R01AG027924, R01AG031784, R01AG035355)
- National Heart, Lung, and Blood Institute (R37HL063762)
- National Institute of Neurological Disorders and Stroke (R37NS034467, P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, APOE isoforms, Alzheimer's disease, APOE ε4, APOE2, apoE receptors, low-density lipoprotein receptor family, ApoER2, VLDLR, LRP1, amyloid-beta, amyloid-beta aggregation, amyloid-beta clearance, lipid modification, synaptic plasticity, neuroinflammation, lipid transport, genetic risk factors, treatment options
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain, Carrier Proteins, Humans, Neuronal Plasticity, Phosphorylation, Amyloid beta-Peptides, Polymorphism, Single Nucleotide, Protein Transport, Low Density Lipoprotein Receptor-Related Protein-1, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.